-
Nirsevimab, sold
under the
brand name Beyfortus, is a
human recombinant monoclonal antibody with
activity against respiratory syncytial virus (RSV). It...
-
introduced nirsevimab, a
prophylactic monoclonal antibody with 75%
efficacy against RSV
cases in
infants under one year.
Europe approved nirsevimab in November...
- Merck, it is in a
phase III
trial as of 2023. It
works differently than
nirsevimab. Odumade,
Oludare A; van Haren,
Simon D; Angelidou,
Asimenia (15 August...
-
squamous cell carcinoma, head and neck cancer,
nasopharyngeal cancer,
glioma Nirsevimab mab
human RSV
fusion glycoprotein respiratory syncytial virus Nivolumab...
-
syncytial virus (RSV) in
infants from
birth through 6
months of age."
Nirsevimab, a
monoclonal antibody against RSV, is
recommended by the CDC for all...
-
Sotrovimab J06BD06
Regdanvimab J06BD07
Casirivimab and
imdevimab J06BD08
Nirsevimab Immune sera and
immunoglobulins for
veterinary use are in the
ATCvet group...
-
Stadium in Inglewood, California. July 17 – The FDA
approves the drug
Nirsevimab, also
known as Beyfortus,
which treats RSV in infants. July 18 – Michigan...
-
benralizumab (anti-IL-5R)
tralokinumab (anti-IL-13)
anifrolumab (anti-IFN-aR)
nirsevimab (anti-RSV) MedImmune, Inc. v. Genentech, Inc. "12
years on,
Astra draws...
- Exbivirumab§ Foravirumab§ Imdevimab† (+casirivimab) Libivirumab§
Maftivimab Nirsevimab†
Odesivimab Pemivibart Rafivirumab§ Regavirumab§
Regdanvimab Sevirumab†...
